[go: up one dir, main page]

CY2004007I2 - (s)-alpha-ethyl-2-oxo-1-pyrrοlidineacetamide - Google Patents

(s)-alpha-ethyl-2-oxo-1-pyrrοlidineacetamide

Info

Publication number
CY2004007I2
CY2004007I2 CY200400007C CY2004007C CY2004007I2 CY 2004007 I2 CY2004007 I2 CY 2004007I2 CY 200400007 C CY200400007 C CY 200400007C CY 2004007 C CY2004007 C CY 2004007C CY 2004007 I2 CY2004007 I2 CY 2004007I2
Authority
CY
Cyprus
Prior art keywords
pyrrolidineacetamide
oxo
alpha
ethyl
Prior art date
Application number
CY200400007C
Other languages
English (en)
Other versions
CY2004007I1 (el
Original Assignee
Ucb, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10560974&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2004007(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb, S.A. filed Critical Ucb, S.A.
Publication of CY2004007I1 publication Critical patent/CY2004007I1/el
Publication of CY2004007I2 publication Critical patent/CY2004007I2/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Detergent Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Seasonings (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CY200400007C 1984-05-15 2004-10-27 (s)-alpha-ethyl-2-oxo-1-pyrrοlidineacetamide CY2004007I2 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB848412357A GB8412357D0 (en) 1984-05-15 1984-05-15 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
CY2004007I1 CY2004007I1 (el) 2009-11-04
CY2004007I2 true CY2004007I2 (el) 2009-11-04

Family

ID=10560974

Family Applications (2)

Application Number Title Priority Date Filing Date
CY1567A CY1567A (en) 1984-05-15 1991-12-20 (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamides
CY200400007C CY2004007I2 (el) 1984-05-15 2004-10-27 (s)-alpha-ethyl-2-oxo-1-pyrrοlidineacetamide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY1567A CY1567A (en) 1984-05-15 1991-12-20 (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamides

Country Status (33)

Country Link
US (3) US4696943A (el)
EP (1) EP0162036B1 (el)
JP (1) JPH0629186B2 (el)
KR (1) KR920003819B1 (el)
CN (1) CN1015541B (el)
AT (1) ATE45567T1 (el)
AU (1) AU574465B2 (el)
BG (2) BG50156A3 (el)
CA (1) CA1235129A (el)
CY (2) CY1567A (el)
DE (3) DE10075021I1 (el)
DK (1) DK163501C (el)
ES (2) ES8704893B9 (el)
FI (1) FI80673C (el)
GB (1) GB8412357D0 (el)
GE (1) GEP20002001B (el)
GR (1) GR851155B (el)
HK (1) HK52391A (el)
IE (1) IE59950B1 (el)
IL (1) IL75179A (el)
LT (1) LT2584B (el)
LU (2) LU90615I2 (el)
LV (1) LV5233A3 (el)
MY (2) MY101725A (el)
NL (1) NL300028I2 (el)
NO (2) NO164534C (el)
PL (2) PL147386B1 (el)
PT (1) PT80460B (el)
SA (1) SA01210656A (el)
SG (1) SG80090G (el)
SU (3) SU1402260A3 (el)
UA (1) UA6158A1 (el)
ZA (1) ZA853635B (el)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827389D0 (en) * 1988-11-23 1988-12-29 Ucb Sa Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide
IT1231477B (it) * 1989-07-12 1991-12-07 Sigma Tau Ind Farmaceuti (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
GB9319732D0 (en) * 1993-09-24 1993-11-10 Ucb Sa Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
US6107492A (en) * 1998-05-08 2000-08-22 Ucb, S.A. Process for the preparation of levetiracetam
US6124473A (en) * 1998-05-08 2000-09-26 Ucb, S.A. Process for preparing (s)- and (R)-α-ethyl-2-oxo-1-pyrrolidineacetamide
EA002379B1 (ru) * 1999-07-21 2002-04-25 Российский Государственный Педагогический Университет Им. А.И.Герцена Средство, обладающее антиишемической, гипотензивной и антигипоксической активностью
EA002380B1 (ru) * 1999-07-21 2002-04-25 Российский Государственный Педагогический Университет Им. А.И.Герцена Антиишемическое средство
EE200200274A (et) * 1999-12-01 2003-06-16 Ucb, S.A. Pürrolidiinatseetamiidi derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud kesknärvisüsteemi häirete ravimiseks, ja farmatseutiline kompositsioon
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6686477B2 (en) 2000-09-29 2004-02-03 Eastman Chemical Company Highly enantiomerically pure lactam-substituted propanoic acid derivatives and methods of making and using same
AU2002224847A1 (en) * 2000-11-21 2002-06-03 U C B, S.A. N-alkylated gaba compounds, processes for their preparation and their use as medicaments
US7608636B2 (en) * 2000-12-28 2009-10-27 Hamilton Pharmaceuticals, Inc. Medicines for treatment and prevention of neurogenic pain
WO2002067931A1 (en) * 2001-02-23 2002-09-06 Johns Hopkins University Treatment of tics, tremors and related disorders
EP1419144B1 (en) 2001-08-10 2008-10-08 UCB Pharma S.A. Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues
HUP0401667A2 (hu) * 2001-10-08 2004-12-28 Ucb, S.A. 2-Oxo-1-pirrolidin-származékok alkalmazása diszkinézia és mozgási rendellenességek kezelésére szolgáló gyógyszer előállítására
RU2216322C1 (ru) * 2002-02-28 2003-11-20 Закрытое акционерное общество "АСГЛ-Фармацевтические Инновации" Средство, обладающее антиишемической, гипотензивной, противоаритмической и ноотропной активностью
WO2003094913A1 (en) * 2002-05-14 2003-11-20 Ucb, S.A. Use of 2-oxo-1-pyrrolidone derivatives for the preparation of a drug
US7132552B2 (en) * 2003-02-03 2006-11-07 Teva Pharmaceutical Industries, Ltd. Process for producing levetiracetam
ES2214147B1 (es) 2003-02-28 2005-10-01 Farma-Lepori S.A. Procedimiento de obtencion de un agente antiepileptico.
TR200503397T1 (tr) * 2003-03-18 2007-03-21 Hetero Drugs Limited Levetirasetam'ın yeni kristal formları.
EP1663968A1 (en) * 2003-09-05 2006-06-07 Ranbaxy Laboratories Limited Process for the preparation of pure levetiracetam
PL1667967T3 (pl) * 2003-09-24 2012-11-30 Ucb Pharma Sa Sposób wytwarzania pochodnych 2-okso-1-pirolidyny
WO2005054188A1 (en) 2003-12-02 2005-06-16 Ucb, S.A. Imidazole derivatives, processes for preparing them and their uses
US7531673B2 (en) 2004-02-18 2009-05-12 Dr. Reddy's Laboratories Limited Preparation of amino acid amides
CA2488325C (en) * 2004-11-22 2010-08-24 Apotex Pharmachem Inc. Improved process for the preparation of (s)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide and (r)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide
EA014249B1 (ru) * 2005-01-27 2010-10-29 Алембик Лимитед Формуляция леветирацетама длительного высвобождения
WO2006088864A1 (en) * 2005-02-16 2006-08-24 Elan Pharma International Limited Controlled release compositions comprising levetiracetam
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
WO2006090265A2 (en) * 2005-02-28 2006-08-31 Ranbaxy Laboratories Limited Processes for the preparation of levetiracetam, its intermediate and the use of levetiracetam in pharmaceutical compositions
EP1863761A1 (en) * 2005-03-10 2007-12-12 Rubamin Limited Process for preparing levetiracetam
US8216611B2 (en) * 2005-03-30 2012-07-10 Mylan Pharmaceuticals Ulc Combined-step process for pharmaceutical compositions
WO2006103696A2 (en) * 2005-04-01 2006-10-05 Rubamin Laboratories Limited Process for preparing levetiracetam and racemization of (r)- and (s)-2-amino butynamide and the corresponding acid derivatives
EP2308867A3 (en) 2005-06-01 2011-10-19 UCB Pharma S.A. 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses
HRP20141185T1 (hr) 2005-07-26 2015-01-30 Ucb Pharma Sa Farmaceutski pripravci koji sadrže levetiracetam i proces za njihovu pripremu
US8338621B2 (en) 2005-12-21 2012-12-25 Ucb S.A. Process for the preparation of 2-oxo-1-pyrrolidine derivatives
CN101360493A (zh) * 2006-01-24 2009-02-04 特瓦制药工业有限公司 左乙拉西坦制剂和制备方法
US20080014271A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
JP2009544656A (ja) * 2006-07-25 2009-12-17 ザック システム エス．ピー．エー． レベチラセタムの調製法
EP2051696A2 (en) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
CN101130504B (zh) * 2006-08-25 2010-07-28 苏州雅本化学股份有限公司 经合成、拆分与消旋化制备手性药物左乙拉西坦中间体(s)-(+)-2-氨基丁酰胺盐酸盐的方法
EP1932922A1 (de) * 2006-12-13 2008-06-18 Desitin Arzneimittel GmbH Schnelltest zum Nachweis von DNA-Sequenzen
WO2008077035A2 (en) * 2006-12-18 2008-06-26 Dr. Reddy's Laboratories Ltd. Processes for the preparation of levetiracetam
CN101333180B (zh) * 2007-06-29 2011-05-18 浙江华海药业股份有限公司 一种制备左乙拉西坦中间体的方法
US20090082422A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched levetiracetam
WO2009050735A1 (en) * 2007-10-15 2009-04-23 Lupin Limited A novel polymorph of levetiracetam and a process for its preparation
US20090263481A1 (en) * 2008-04-17 2009-10-22 Atul Vishvanath Patil Levetiracetam formulations
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
EP2147911A1 (en) 2008-07-24 2010-01-27 ZaCh System S.p.A. Process for the preparation of levetiracetam
US20100190752A1 (en) 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
ES2865504T3 (es) * 2008-10-16 2021-10-15 Univ Johns Hopkins Procedimientos y composiciones para la mejora de la función cognitiva
EP2179725A1 (en) 2008-10-23 2010-04-28 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising levetiracetam
EP2341777B1 (en) * 2008-11-07 2015-01-21 NovaBay Pharmaceuticals, Inc. Antimicrobial oxazolidinone, hydantoin and imidazolidinone compositions
US20100159009A1 (en) * 2008-12-24 2010-06-24 Zhongshui Yu Controlled-release formulations
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
US8785661B2 (en) 2009-05-13 2014-07-22 Nektar Therapeutics Oligome-containing pyrrolidine compounds
CN101885696A (zh) * 2009-05-14 2010-11-17 上海华理生物医药有限公司 一种合成高纯度左乙拉西坦的方法
EP2461808A2 (en) 2009-08-07 2012-06-13 UCB Pharma S.A. Methods for enhancing the cognitive function
EP2298290A1 (en) 2009-09-16 2011-03-23 LEK Pharmaceuticals d.d. Controlled release composition comprising levetiracetam
US7939676B2 (en) * 2009-09-17 2011-05-10 Zach System S.P.A. Process for the preparation of levetiracetam
DK2491045T3 (en) 2009-10-23 2016-03-14 Ucb Biopharma Sprl 2-oxo-1-pyrrolidinylimidazothiadiazolderivativer
EP2533645B1 (en) * 2010-02-09 2016-07-27 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2539444A4 (en) 2010-02-26 2013-09-18 Univ California COMPOSITIONS AND METHODS FOR THE PRODUCTION OF L-HOMOALANINE
WO2011136751A2 (en) 2010-04-26 2011-11-03 Mahmut Bilgic Water soluble pharmaceutical composition
US9333175B2 (en) 2010-06-16 2016-05-10 Mylan Inc. Controlled release levetiracetam formulations and methods for producing the same
EP2492354A1 (en) 2011-02-23 2012-08-29 Institut National De La Recherche Agronomique (INRA) Method for identifying compounds useful in the treatment of photosensitive reflex epilepsy
US8957218B2 (en) 2011-04-18 2015-02-17 Ucb Pharma S.A. 2-oxo-1-imidazolidinyl imidazothiadiazole derivatives
EP2524910A1 (en) 2011-05-17 2012-11-21 DSM IP Assets B.V. Process for the resolution of aminobutyramide
CN102382027B (zh) * 2011-09-20 2013-11-13 浙江江北药业有限公司 一种左乙拉西坦的制备方法
CN102617436B (zh) * 2012-03-20 2014-02-12 浙江洪波化工有限公司 2-(2-氧代吡咯烷基）丁酰胺的制备方法
CN102633675A (zh) * 2012-04-10 2012-08-15 南京大学 一种dl-2-氨基丁酰胺制备方法
CN102675181B (zh) * 2012-06-07 2013-11-20 北京师宏药物研制中心 一种左乙拉西坦的制备方法
CN102702063B (zh) * 2012-06-15 2013-09-04 孙威 一种左乙拉西坦制备方法
WO2014012563A1 (en) 2012-07-20 2014-01-23 Ucb Pharma, S.A. Compounds for enhancing the cognitive function
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHOD AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA
CN103012190B (zh) * 2012-12-05 2015-03-18 江苏拜克新材料有限公司 一种s-2-氨基丁酰胺盐酸盐的合成方法
US9339489B2 (en) 2013-03-15 2016-05-17 Aprecia Pharmaceuticals Company Rapid disperse dosage form containing levetiracetam
EP3431141B1 (en) 2013-03-15 2021-12-08 Aprecia Pharmaceuticals LLC Three-dimensional printing method
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
EP3827820A1 (en) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam for improving cognitive function
PH12019500127B1 (en) 2014-01-21 2022-05-04 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
EP3424535A1 (en) 2014-01-21 2019-01-09 Janssen Pharmaceutica NV Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
CN103922988A (zh) * 2014-04-29 2014-07-16 苏州天马精细化学品股份有限公司 一种左乙拉西坦粗品的纯化方法
CN103910649A (zh) * 2014-04-29 2014-07-09 苏州天马精细化学品股份有限公司 一种左乙拉西坦中间体（s）-n-[1-(氨基羰基)丙基]-4-氯代丁酰胺的合成方法
CN104860863B (zh) * 2015-04-10 2017-06-20 惠州信立泰药业有限公司 左乙拉西坦和含其的药物组合物
CN112843005B (zh) 2015-05-22 2023-02-21 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
EP3397253A1 (en) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
CN106432032B (zh) * 2016-09-14 2019-07-12 苏州天马药业有限公司 一种左乙拉西坦的制备方法
CN106591179B (zh) * 2016-12-05 2018-07-03 长兴制药股份有限公司 甲基包囊菌及其在选择性拆分制备(S)-α-乙基-2-氧-1-吡咯烷乙酸盐上的应用
LT3554490T (lt) 2016-12-16 2022-04-25 Idorsia Pharmaceuticals Ltd Farmacinis derinys, apimantis t tipo kalcio kanalo blokatorių
CN108503610B (zh) 2017-02-24 2019-09-13 北京艾百诺医药股份有限公司 一种光学纯的(r)-4-正丙基-二氢呋喃-2(3h)-酮的制备方法
CN107337628B (zh) * 2017-08-10 2022-02-08 浙江华海药业股份有限公司 一种制备左乙拉西坦的方法
TWI826531B (zh) 2018-09-21 2023-12-21 南韓商愛思開生物製藥股份有限公司 具有㗁二唑之化合物及包含該化合物之醫藥組合物
CN110003074A (zh) 2019-04-23 2019-07-12 浙江华海药业股份有限公司 一种左乙拉西坦中间体的制备方法
TW202114655A (zh) 2019-08-14 2021-04-16 瑞士商辛鐵堤卡公司 左乙拉西坦(levetiracetam)之鞘內投藥
US11384050B1 (en) 2021-02-03 2022-07-12 Vitaworks Ip, Llc Method for preparing levetiracetam and intermediates thereof
IL305471A (en) 2021-02-26 2023-10-01 Syndesi Therapeutics Sa Compounds for the treatment of cognitive disorders
CN113979911A (zh) * 2021-11-12 2022-01-28 汤斌 一种从大鲵肽中提取乙拉西坦的方法
US20240368081A1 (en) * 2023-05-05 2024-11-07 Suzhou Brighthope Pharmatech Co., Ltd Process for the production of levetiracetam and intermediate thereof
US20240368082A1 (en) * 2023-05-05 2024-11-07 Suzhou Brighthope Pharmatech Co., Ltd Process for the production of levetiracetam and intermediate thereof
US20240368080A1 (en) * 2023-05-05 2024-11-07 Suzhou Brighthope Pharmatech Co., Ltd Process for the production of levetiracetam and intermediate thereof
US20240409511A1 (en) * 2023-06-12 2024-12-12 Suzhou Brighthope Pharmatech Co., Ltd Process for the production of levetiracetam and intermediates thereof
WO2025132331A1 (en) 2023-12-21 2025-06-26 UCB Biopharma SRL Compounds for treatment of a hyperkinetic movement disorder

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1309692A (en) * 1970-02-13 1973-03-14 Ucb Sa N-substituted lactams
GB1583871A (en) * 1976-10-19 1981-02-04 Ucb Sa Anti-aggregants
FR2418790A1 (fr) * 1978-03-02 1979-09-28 Philagro Sa Nouveaux derives de pyrrolidinone-2 et compositions herbicides les contenant
GB8412358D0 (en) * 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition

Also Published As

Publication number Publication date
DK163501C (da) 1992-07-27
AU574465B2 (en) 1988-07-07
DE10075021I1 (de) 2000-10-19
LU90682I2 (fr) 2001-01-30
UA6158A1 (uk) 1994-12-29
PT80460B (pt) 1987-08-19
DE10199005I2 (de) 2002-03-14
ES543124A0 (es) 1986-06-16
DK163501B (da) 1992-03-09
NL300028I1 (nl) 2001-02-01
PT80460A (fr) 1985-06-01
PL144346B1 (en) 1988-05-31
CY2004007I1 (el) 2009-11-04
SU1428195A3 (ru) 1988-09-30
DE3572348D1 (de) 1989-09-21
FI851875L (fi) 1985-11-16
FI851875A0 (fi) 1985-05-13
PL257385A1 (en) 1986-10-07
PL147386B1 (en) 1989-05-31
GEP20002001B (en) 2000-03-10
HK52391A (en) 1991-07-19
CN85105301A (zh) 1987-01-14
NO851933L (no) 1985-11-18
EP0162036B1 (fr) 1989-08-16
ATE45567T1 (de) 1989-09-15
ES8704893A1 (es) 1987-04-16
EP0162036A1 (fr) 1985-11-21
ZA853635B (en) 1985-12-24
FI80673C (fi) 1990-07-10
PL253374A1 (en) 1986-05-06
AU4253085A (en) 1986-11-20
DE10199005I1 (de) 2001-07-12
LT2584B (lt) 1994-03-25
BG47497A3 (en) 1990-07-16
ES8704893B9 (es) 2012-02-07
KR850008336A (ko) 1985-12-16
DK212985D0 (da) 1985-05-14
ES8608485A1 (es) 1986-06-16
CN1015541B (zh) 1992-02-19
NO164534C (no) 1990-10-17
US4837223A (en) 1989-06-06
SU1430392A1 (ru) 1988-10-15
KR920003819B1 (ko) 1992-05-15
IL75179A0 (en) 1985-09-29
LV5233A3 (lv) 1993-10-10
GB8412357D0 (en) 1984-06-20
BG50156A3 (en) 1992-05-15
CA1235129A (en) 1988-04-12
US4943639A (en) 1990-07-24
CY1567A (en) 1991-12-20
DK212985A (da) 1985-11-16
IL75179A (en) 1988-05-31
JPH0629186B2 (ja) 1994-04-20
MY101726A (en) 1992-01-17
MY101725A (en) 1992-01-17
GR851155B (el) 1985-11-25
NL300028I2 (nl) 2001-06-01
LU90615I2 (fr) 2000-10-02
SU1402260A3 (ru) 1988-06-07
IE851193L (en) 1985-11-15
NO164534B (no) 1990-07-09
US4696943A (en) 1987-09-29
NO2001008I2 (no) 2005-05-30
SA01210656A (ar) 2005-12-03
JPS60252461A (ja) 1985-12-13
SG80090G (en) 1990-11-23
IE59950B1 (en) 1994-05-04
FI80673B (fi) 1990-03-30

Similar Documents

Publication Publication Date Title
CY2004007I2 (el) (s)-alpha-ethyl-2-oxo-1-pyrrοlidineacetamide
AT380762B (de) Hoergeraet
AT379929B (de) Hoergeraet
SE8501891L (sv) Bildoverforingssystem
ATA98284A (de) Schalplatte
AT386724B (de) Haecksler
ATA135485A (de) Maishaecksler
ATA237384A (de) Maehwerk
ATE36715T1 (de) 7-d-mandelamido-3-(1-sulfomethyltetrazol-5us840229
ATA45484A (de) Kimme
AT389296B (de) Elektrokoagulator
BR8402733A (pt) Divisoria
AR231237A1 (es) Calzado-patin
BR8406630A (pt) Volumometro
BR8401156A (pt) Auto-balsa
BR8406874A (pt) Bucha
FI840121A0 (fi) Jordstraolningsskydd
IT8466703A0 (it) Economy-control-gas
BR8405625A (pt) Gasogenio
BR8405261A (pt) Auto-balsa
ATA406084A (de) Schipasshalter
BR6400357U (pt) Moto-bomba
BR8404648A (pt) Minifone
BR8404566A (pt) Paramortecedor
BR8404385A (pt) Regua nautica